Endothelin in health and disease: Endothelin receptor antagonists in the management of pulmonary artery hypertension

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 7, Issue 1, 2002, Pages 9-19

  Kim, Nick H S ^a   Rubin, Lewis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelin; Pulmonary hypertension

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; ANTICOAGULANT AGENT; ATRASENTAN; BERAPROST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BMS 193884; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DARUSENTAN; DILTIAZEM; ENDOTHELIN; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; ILOPROST; INOTROPIC AGENT; NIFEDIPINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; SITAXSENTAN; TEZOSENTAN; UNCLASSIFIED DRUG; UNIPROST; VASODILATOR AGENT; WARFARIN;

ALGORITHM; BLOOD VESSEL INJURY; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFECT; HUMAN; LUNG TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036117987     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840200700i102     Document Type: Review

References (94)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. The discovery of endothelins
3. Endothelial cell responses to hypoxic stress
4. The endothelin family of peptides: Local hormones with diverse roles in health and disease?
5. Endothelins and the lung
6. Role of endothelin-1 in regulating proliferation of cultured rabbit airway smooth muscle cells
7. Mitogenic actions of endothelin-1 and epidermal growth factor in cultured airway smooth muscle
8. The role of endothelin in the control of adrenocortical function: Stimulation of endothelin release by ACTH and the effects of endothelin-1 and endothelin-3 on steroidogenesis in rat and human adrenocortical cells
9. Mechanisms of ET-1 potentiation of angiotensin II stimulation of aldosterone production
10. Endothelins stimulate aldosterone secretion from dispersed rat adrenal zona glomerulosa cells, acting through ETB receptors coupled with the phospholipase C-dependent signaling pathway
11. B) receptor-activated potentiation of cholinergic nerve-mediated contraction in human bronchus
12. Endothelin-1 augments pressor response to angiotensin II infusion in rats
13. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
14. Endothelin: An endothelium-derived vasoactive peptide
15. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo
16. Different electrical responses to vasoactive agonists in morphologically distinct smooth muscle cell types
17. Subcellular mechanisms of endothelin action in vascular system
18. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo
19. Endothelins
20. Endothelin antagonists
21. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart
22. Role of ET(A) receptors in the regulation of vascular reactivity in rats with congestive heart failure
23. Altered endothelin receptor subtype expression in hepatic injury after ischemia/reperfusion
24. Elevated perfusion pressure upregulates endothelin-1 and endothelin B receptor expression in the rabbit carotid artery
25. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease
26. Role of endothelin in the increased vascular tone of patients with essential hypertension
27. Endothelin receptors in cultured adult rat cardiac fibroblasts
28. Effects of Ro 47-0203 on endothelin-1 and sarafotoxin S6c-induced contractions of human bronchus and guinea-pig trachea
29. ET-1 induces mitogenesis in ovine airway smooth muscle cells via ETA and ETB receptors
30. Acute pro-inflammatory actions of endothelin-1 in the guinea-pig lung: Involvement of ETA and ETB receptors
31. Signaling pathways involved in the A and B receptor-mediated cortisol secretagogue effect of endothelins in the human adrenal cortex
32. Endothelin-1 stimulates aldosterone synthesis in Conn's adenomas via both A and B receptors coupled with the protein kinase C- and cyclooxygenase-dependent signaling pathways
33. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats
34. Clinical experience with endothelin receptor antagonists in chronic heart failure
35. EndothelinB receptor-mediated contraction in human pulmonary resistance arteries
36. Endothelin system-dependent cardiac remodeling in renovascular hypertension
37. Endothelin-1 stimulates cardiac fibroblast proliferation through activation of protein kinase C
38. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB 209670
39. Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors. Role of suppression of endogenous endothelin secretion
40. Influence of pulmonary blood pressure and flow on endothelin-1 production in humans
41. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro
42. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension
43. Pathophysiology of endothelin in the cardiovascular system
44. Endothelin-1-induced bronchoconstriction in asthma
45. Endothelins: A role in cerebrovascular disease?
46. Endothelins in health and disease: An overview
47. Endothelins in chronic liver disease
48. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer
49. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs
50. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure
51. Acute hemodynamic and neurohumoral effects of selective ETa receptor blockade in patients with congestive heart failure
52. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure
53. Acute and short-term effects of the non-peptide endothelin-1 receptor antagonists bosentan in humans
54. Chronic selective ETa receptor blockade in congestive heart failure: The HEAT trial
55. Enrasentan cooperative randomized evaluation (ENCOR)
56. Multicenter, double-blind, placebo controlled study of long-term endothelin blockade with bosentan in chronic heart failure: Results of the REACH-1 trial
57. Update of REACH-1 and MERIT-HF clinical trials in heart failure
58. Long-term, open-label experience with an endothelin receptor antagonist, bosentan, in patients with severe chronic heart failure
59. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension
60. Bosentan, a dual endothelin receptor antagonist, improves exercise capacity and hemodynamics in patients with pulmonary arterial hypertension: Results of a double-blind, randomized, placebo-controlled trial
61. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study
62. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist
63. The endothelin antagonist bosentan: Hemodynamic effects during normoxia and hypoxic pulmonary hypertension in pigs
64. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats
65. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats
66. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats
67. The orally active ETA receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats
68. Pulmonary hypertension
69. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family
70. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred
71. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
72. Primary pulmonary hypertension
73. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: Evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy
74. Primary pulmonary hypertension. A national prospective study
75. Primary pulmonary hypertension
76. Pulmonary hypertension: Diagnostics and therapeutics
77. Primary pulmonary hypertension. Case series from France
78. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry
79. Primary pulmonary hypertension. Case series from the United Kingdom
80. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
81. Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension
82. Primary pulmonary hypertension: Natural history and the importance of thrombosis
83. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial
84. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation
85. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
86. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin
87. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial
88. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
89. Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension
90. Acute hemodynamic effects of subcutaneous UT-15 in primary pulmonary hypertension
91. Medical and surgical treatment options for pulmonary hypertension
92. The Registry of the International Society for Heart and Lung Transplantation: Fourteenth official report - 1997
93. Efficacy and safety of chronic treatment with the oral selective endothelin-A receptor blocker sitaxsentan in pulmonary arterial hypertension (PAH)